Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: J Am Acad Dermatol. 2015 Oct;73(4):705–706. doi: 10.1016/j.jaad.2015.06.063

Table 1. Patient Assessments on Spironolactone.

Patients with FPHL being treated with spironolactone assessed their response.

Retrospective Study Survey Study
Worse Thinning 0 15%
(n=3/20)
No Change 26%
(n=5/19)		 45%
(n=9/20)
Mild Improvement 42.1%
(n=8/19)		 20%
(n=4/20)
Increased Thickness 31.6%
(n=6/19)		 10%
(n=2/20)
No Response N/A 10%
(n=2/20)